Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.

Our focus

We are focusing on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).

We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and our vision is to be a leader in providing treatments for rare diseases in these areas with high unmet medical needs.

Meet our Board of Directors

Thomas Meier, PhD

Founder, Chairman of the Board and the Scientific Committee, Member of the Compensation and Audit & Compliance Committees

Read more

​Philipp Gutzwiller

Board Member and Chairman of the Audit & Compliance Committee

Read more

Bradley C. Meyer

Board Member and Chairman of the Compensation Committee

Read more

Meet our Executive Committee

Stephanie Brown

President North America

Read more

Shabir Hasham, MD

Chief Medical Officer

Read more

Günther Metz, PhD

Head Business Development, EVP

Read more

Oliver Strub

General Counsel & Secretary to the Board, EVP

Read more

Meet our Extended Management Team

Sarah Holmes-Klotz

Head of People & Culture

Read more

Eva Kalias

Head Investor Relations & Communications

Read more

Neville Kodkani, MD

Head Global Marketing & Partner Management

Read more

Marc Schrader

Head Technical Development & Operations

Read more

Geert Jan van Daal, MD, PhD

Head European Affiliates & EU Market Access

Read more